Mirati Therapeutics (MRTX) PT Lowered to $150 at Stifel, Following Weak Amgen's Lumakras Data, AMGN's Lower Estimate Will Dominate Sentiment
Tweet Send to a Friend
Stifel analyst Ben Burnett lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $150.00 (from $235.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
